Blog

Practical Dosimetry in Theranostics: A Guide for Resource-Constrained Clinics

David Mirando — Wed, 02 Apr 2025 12:00:00 GMT

Personalized Dosimetry Enhances Theranostics

The rapid adoption of PSMA-targeted Theranostics shows promise. The soon-to-be-completed Phase III trials PSMAfore, PSMAddition, SPLASH, and ECLIPSE investigate the use of these drugs in earlier-stage metastatic prostate cancers, potentially opening access to a vast population of patients.

How Does Quantitative Data Help in Patient Selection for 177Lu-PSMA-617 Theranostics?

kngai@mimsoftware.com (Ken Ngai) — Tue, 01 Apr 2025 12:27:07 GMT

A review of recent literature shows promising evidence: Total tumor burden (TTB) metrics can aid physicians in their decision-making process to determine who will benefit most from ¹¹⁷Lu-PSMA-617 radioligand therapy (RLT).

How Can You Realize the Promise of Theranostics?

ndwivedi@mimsoftware.com (Neha Dwivedi) — Mon, 31 Mar 2025 12:00:00 GMT

Theranostics—the combination of radiopharmaceutical therapeutics and diagnostics—is a rapidly evolving treatment approach that offers new promise for precise, individualized healthcare. Experts predict that Theranostics will continue growing and will likely be used to treat a wider range of cancers and other diseases in the coming years.¹

How Can You Treat Patients More Quickly?

rcole@mimsoftware.com (Ryan Cole) — Wed, 17 Apr 2024 17:34:11 GMT

3 Ways Radiation Oncology Clinics Are Reducing Simulation-to-Treatment Time

3 Challenges That Stand in the Way of Accurate Target Volumes

jkuhn@mimsoftware.com (Jeff Kuhn) — Wed, 14 Feb 2024 16:13:47 GMT

Precise treatments depend on accurate target volumes (TVs). This is especially true for hypofractionated treatments involving higher radiation doses over fewer fractions with increased risk of toxicity.

Reliance on Max IP in Tumor Motion Management: A Flawed Approach

jkuhn@mimsoftware.com (Jeff Kuhn) — Mon, 27 Nov 2023 14:37:16 GMT

Few things are more challenging for Radiation Therapy treatment planners than tumors that move. In lung cancer cases and other scenarios involving respiratory movement, accurately and efficiently contouring the internal target volume (ITV) is the key challenge to overcome.

Can You Trust Your Deformable Image Registration (DIR) Solution?

jkuhn@mimsoftware.com (Jeff Kuhn) — Thu, 26 Oct 2023 14:59:37 GMT

The key to trusting a DIR is assessing its accuracy—but not all image registration systems give you the tools to do this confidently. A guide by leading Radiation Oncology practitioners shows how image registration vendors compare.

Adopt AI Auto-Contouring without Disrupting Your Radiation Oncology Workflow

jobman@mimsoftware.com (Jay Obman) — Mon, 05 Jun 2023 12:00:00 GMT

The use of AI technology has transformed the field of Radiation Oncology treatment planning. This is particularly true with the introduction of AI auto-contouring, which promises to improve the planning workflow by decreasing the time spent on OAR contour creation and increasing overall plan quality.

Embrace Standardization in Nuclear Medicine: A Case for Improved Patient Care

msirosky@mimsoftware.com (Mike Sirosky) — Tue, 16 May 2023 20:27:04 GMT

Nuclear Medicine departments are essential to healthcare organizations, providing patients with specialized diagnostic and therapeutic services. Despite their critical role, these departments often struggle when using multiple disparate systems across their organization. The use of too many systems can create significant obstacles for healthcare providers, ultimately diminishing the quality of care provided to patients. These systems often sit in isolation, leading to data silos and difficulty when clinicians compare and analyze information from different organizations, cameras, and processing softwares. The need for better integration becomes even more critical in remote and mobile work environments.

Handling Increasing Reirradiation Cases: What’s Your Plan?

eabbott@mimsoftware.com (Elliot Abbott) — Mon, 01 May 2023 13:26:46 GMT